Editas Medicine Inc. (tidligere kendt som Gengine Inc.) blev grundlagt i 2013 og er baseret i Cambridge, Massachusetts. De har fokus på udviklingen af en genom-redigeringsplatform rettet mod genetisk definerede sygdomme uden en eksisterende godkendt løsning. Selskabets proces er baseret på en unik teknologi... Vis
There's one week left of Webinars for January 2022 🎓 Don't worry - we still have another 11 months in 2022 to bring you fresh weekly webinars!
Here's what's happening this week:
👉 Monday, January 24th, at 13:00 (GMT).
- 𝐖𝐞𝐞𝐤𝐥𝐲 𝐎𝐮𝐭𝐥𝐨𝐨𝐤: Focusing on the main driving forces... Vis Oversæt
Today's market event and portfolio modifications require an update from me.
First of all, my apologies for not finishing 2021 in green, with a yearly negative return of -3.5%. This was mostly due to significant losses on CRISPR stocks $EDIT (Editas Medicine Inc), $NTLA (Intellia Therapeutics... Vis Oversæt
$EDIT (Editas Medicine Inc) The big news for Editas this month came from its EDIT-301 investigational new drug (IND) application.
Editas announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for EDIT-301. This is the... Vis Oversæt
$EDIT (Editas Medicine Inc) Bought this nearly 5 years ago... watched it gain over 500%... and now just 7% in profit. I'm still not seeing signs of a reversal of the trend, but I'll certainly be buying more when it does.... Vis Oversæt